Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Law

Showing results (261-270 of 278) with videos related to

Pageof 28
Sort By:
AIDS Care|July 20, 2018
Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in AsiaAwachana Jiamsakul, Stephen J Kerr, Sasisopin Kiertiburanakul, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2024
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort ConsortiumDhanushi Rupasinghe, Loveleen Bansi-Matharu, Matthew Law, et al.
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
Tropical Medicine & International Health : TM & IH|March 8, 2016
Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHODAwachana Jiamsakul, Stephen J Kerr, Oon Tek Ng, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
AIDS Research and Therapy|May 10, 2017
Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settingsSasisopin Kiertiburanakul, David Boettiger, Oon Tek Ng, et al.
Antiviral Therapy|June 13, 2015
Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational DatabaseDavid C Boettiger, Stephen Kerr, Rossana Ditangco, et al.
Antiviral Therapy|April 12, 2021
Treatment modification after second-line failure among people living with HIV in the Asia-PacificAwachana Jiamsakul, Iskandar Azwa, Fujie Zhang, et al.
Plos One|September 4, 2014
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational databaseDavid Charles Boettiger, Stephen Kerr, Rossana Ditangco, et al.
Journal of the International AIDS Society|August 26, 2022
Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in AsiaSirinya Teeraananchai, Matthew Law, David Boettiger, et al.
Pageof 28

Showing results (261-270 of 278) with videos related to

Sort By:
Pageof 28
AIDS Care|July 20, 2018
Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in AsiaAwachana Jiamsakul, Stephen J Kerr, Sasisopin Kiertiburanakul, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2024
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort ConsortiumDhanushi Rupasinghe, Loveleen Bansi-Matharu, Matthew Law, et al.
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
Tropical Medicine & International Health : TM & IH|March 8, 2016
Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHODAwachana Jiamsakul, Stephen J Kerr, Oon Tek Ng, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
AIDS Research and Therapy|May 10, 2017
Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settingsSasisopin Kiertiburanakul, David Boettiger, Oon Tek Ng, et al.
Antiviral Therapy|June 13, 2015
Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational DatabaseDavid C Boettiger, Stephen Kerr, Rossana Ditangco, et al.
Antiviral Therapy|April 12, 2021
Treatment modification after second-line failure among people living with HIV in the Asia-PacificAwachana Jiamsakul, Iskandar Azwa, Fujie Zhang, et al.
Plos One|September 4, 2014
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational databaseDavid Charles Boettiger, Stephen Kerr, Rossana Ditangco, et al.
Journal of the International AIDS Society|August 26, 2022
Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in AsiaSirinya Teeraananchai, Matthew Law, David Boettiger, et al.
Pageof 28